Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil

Brain

Volumn 136, Issue 5, 2013, Pages 1568-1577

  Thobois, Stéphane ^a,b   Lhommée, Eugénie ^c   Klinger, Hélène ^a   Ardouin, Claire ^c   Schmitt, Emmanuelle ^c   Bichon, Amélie ^c   Kistner, Andrea ^c   Castrioto, Anna ^c   Xie, Jing ^a   Fraix, Valerie ^c   Pelissier, Pierre ^c   Chabardes, Stephan ^d   Mertens, Patrick ^a   Quesada, Jean Louis ^e   Bosson, Jean Luc ^e   Pollak, Pierre ^c   Broussolle, Emmanuel ^a,b   Krack, Paul ^c  

^a UNIVERSITÉ LYON 1   (France)

^b INSTITUT DES SCIENCES COGNITIVES   (France)

^c UNIV GRENOBLE ALPES   (France)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

^e Joseph Fourier University   (France)

Author keywords

apathy; dopamine agonist; Parkinson; piribedil; subthalamic nucleus

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; PIRIBEDIL; PLACEBO;

ADULT; ANHEDONIA; ANXIETY; APATHY; ARTICLE; BECK ANXIETY INVENTORY; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DYSKINESIA; FEMALE; FOLLOW UP; HALLUCINATION; HAMILTON SCALE; HUMAN; INTENTION TO TREAT ANALYSIS; IRRITABILITY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CARCINOMA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; STOMACH PAIN;

EID: 84877296484     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awt067     Document Type: Article

References (46)

1. Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson's disease. Mov Disord 2009; 24: 2175-86.
2. Ardouin C, Ché reau I, Llorca PM, Lhommé e E, Durif F, Pollak P, et al. Assessment of hyper-and hypodopaminergic behaviors in Parkinson's disease. Rev Neurol (Paris) 2009; 165: 845-56.
3. Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 573-80.
4. Beck A, Ward C, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-71.
5. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988; 56: 893-7.
6. Benito-Leon J, Cubo E, Coronell C. Impact of apathy on health-related quality of life in recently diagnosed Parkinson's diseae: the ANIMO study. Mov Disord 2012; 27: 211-8.
7. Bó di N, Ké ri S, Nagy H, Moustafa A, Myers CE, Daw N, et al. Reward-learning and the novelty-seeking personality: a betweenand within-subjects study of the effects of dopamine agonists on young Parkinson's patients. Brain 2009; 132 (Pt 9): 2385-95.
8. Castro-Caldas A, Delwaide P, Jost W, Merello M, Williams A, Lamberti P, et al. The Parkinson-Control study: a 1-year randomized, doubleblind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease. Mov Disord 2006; 21: 500-9.
9. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009; 8: 464-74.
10. Czernecki V, Schü pbach M, Yaici S, Lé vy R, Bardinet E, Yelnik J, et al. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov Disord 2008; 23: 964-9.
11. Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schä fer H, Bö tzel K, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006; 355: 896-908.
12. Dujardin K, Defebvre L. Apathy in Parkinson's disease: what are the underlying mechanisms. Neurology 2012; 79: 1082-3.
13. Even C, Weintraub D. Is depression in Parkinson's disease (PD) a specific entity? J Affect Disord 2012; 139: 103-12.
14. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010; 303: 47-53.
15. Funkiewiez A, Ardouin C, Caputo E, Krack P, Fraix V, Klinger H, et al. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75: 834-9.
16. Gallagher DA, Schrag A. Psychosis, apathy, depression and anxiety in Parkinson's disease. Neurobiol Dis 2012; 46: 581-9.
17. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
18. Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003; 349: 1925-34.
19. Leentjens AF, Koester J, Fruh B, Shephard DT, Barone P, Houben JJ. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies. Clin Ther 2009; 31: 89-98.
20. Lemke MR, Brecht HM, Koester J, Kraus PH, Reichmann H. Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci 2005; 17: 214-20.
21. Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex 2006; 16: 916-28.
22. Lhommé e E, Klinger H, Thobois S, Schmitt E, Ardouin C, Bichon A, et al. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours. Brain 2012: 135 (Pt 5): 1463-77.
23. Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffmann D, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 1998; 339: 1105-11.
24. Millan M. From the cell to the clinic: a comparative review of the partial D2/D3receptor agonist and 2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease. Pharmacol Ther 2010; 128: 229-73.
25. Moreau C, Delval A, Defebvre L, Dujardin K, Duhamel A, Petyt G, et al. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol 2012; 11: 589-596.
26. Odekerken VJ, van Laar T, Staal MJ, Mosch A, Hoffmann CF, Nijssen PC, et al. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial. Lancet Neurol 2013; 12: 37-44.
27. Pluck G, Brown RG. Apathy in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002; 73: 636-42.
28. Pondal M, Marras C, Miyasaki J, Moro E, Armstrong MJ, Strafella AP, et al. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J Neurol Neurosurg Psychiatry 2013; 84: 130-5.
29. Post RM, Gerner RH, Carman JS, Gillin JC, Jimerson DC, Goodwin FK, et al. Effects of a dopamine agonist piribedil in depressed patients: relationship of pretreatment homovanillic acid to antidepressant response. Arch Gen Psychiatry 1978; 35: 609-15.
30. Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010; 67: 58-63.
31. Rascol O, Dubois B, Caldas AC, Senn S, Del Signore S, Lees A, Parkinson REGAIN Study Group. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study. Mov Disord 2006; 21: 2110-5.
32. Rascol O, Azulay JP, Blin O, Bonnet AM, Brefel-Courbon C, Cé saro P, et al. Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over study. Mov Disord 2010; 25: 368-76.
33. Rektorova I, Balaz M, Svatova J, Zarubova K, Honig I, Dostal V, et al. Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study. Clin Neuropharmacol 2008; 31: 261-6.
34. Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005; 128 (Pt 6): 1314-22.
35. Robert PH, Clairet S, Benoit M, Koutaich J, Bertogliati C, Tible O, et al. The apathy inventory: assessment of apathy and awareness in Alzheimer's disease, Parkinson's disease and mild cognitive impairment. Int J Geriatr Psychiatry 2002; 17: 1099-105.
36. Sackett D, Haynes R, Guyatt G, Tugwell P. Clinical epidemiology. A basic science for clinical medicine. 2ns edn. Boston: Little, Brown and Co; 1991. p. 441.
37. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000; 69: 308-12.
38. Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P. A scale for the assessment of hedonic tone: the Snaith-Hamilton pleasure scale. Br J Psychiatry 1995; 167: 99-103.
39. Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E, et al. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 2006; 5: 25-43.
40. Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992; 4: 134-9.
41. Starkstein SE. Apathy in Parkinson's disease: diagnostic and etiological dilemmas. Mov Disord 2012; 27: 174-8.
42. Thobois S, Ardouin C, Lhommé e E, Klinger H, Lagrange C, Xie J, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain 2010; 133 (Pt 4): 1111-27.
43. Voon V, Fernagut PO, Wickens J, Baunez C, Rodriguez M, Pavon N, et al. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol 2009; 8: 1140-9.
44. Voon V, Krack P, Lang AE, Lozano AM, Dujardin K, Schü pbach M, et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain 2008; 131 (Pt 10): 2720-8.
45. Witt K, Daniels C, Reiff J, Krack P, Volkmann J, Pinsker MO, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. Lancet Neurol 2008; 7: 605-14.
46. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-35.